Kevin Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin Ho has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Gilbert C. Walker
University of Toronto
7 shared publications - Kenneth Tran
Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada
3 shared publications Kris S. Kim
Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada
3 shared publicationsLeonid Gilburd
Department of Chemistry, University of Toronto, Toronto, Ontario M5S 3H6, Canada
3 shared publications- Mitchell A. Winnik
Department of Chemistry University of Toronto Toronto Ontario Canada
3 shared publications - Sissi de Beer
Department of Molecules & Materials MESA+ Institute University of Twente Enschede The Netherlands
3 shared publications
Latest Publications
- Open Access
- 10 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e44027
Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial
Background: Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti–heart failure therapies include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is). Both classes have demonstrated mortality and morbidity benefits. Although these new therapies have morbidity and mortality benefits, it is not known whether rapid initiation is beneficial when compared with the conventional, slower-stepped approach. Many clinicians have been taught that starting with low-dose therapies and gradually increasing the dose is a safe way of intensifying treatment regimens. Pharmacologically, it is rational to use a combination of drugs that target multiple pathological mechanisms, as there is potential synergism and better therapeutic outcomes. Theoretically, the quicker the right combinations are used, the more likely the beneficial effects will be experienced. However, rapid up-titration must be balanced with patient safety and tolerability. Objective: This study aims to determine if early addition of ARNIs, SGLT2is, β-blockers, and mineralocorticoid receptor antagonists (within 4 weeks), when compared with the same therapies initiated slower (within 6 months), will reduce all-cause mortality and hospitalizations for heart failure in patients with stable heart failure with reduced ejection fraction. Methods: This is a single-center, randomized controlled, double-arm, assessor-blinded, active control, and pragmatic clinical trial. Adults with stable heart failure with reduced ejection fraction and idiopathic dilated cardiomyopathy will be randomized to conventional sequencing (the control arm; over 6 months) of anti–heart failure therapies, and a second arm will receive rapid sequencing (over 4 weeks). Study participants will be followed for 5 years to assess the safety, efficacy, and tolerability of the 2 types of sequencing. Posttrial access and care will be provided to all study participants throughout their lifespan. Results: We are currently in the process of obtaining ethical clearance and funding. Conclusions: We envisage that this study will help support evidence-based medicine and inform clinical practice guidelines on the optimal rate of sequencing of anti–heart failure therapies. A third placebo arm was considered, but costs would be too much and not providing study participants with therapies with known morbidity and mortality benefits may be unethical, in our opinion. Given the post–COVID-19 economic downturn and posttrial access to interventions, a major challenge will be acquiring funding for this study. International Registered Report Identifier (IRRID): PRR1-10.2196/44027
- 10 March 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e44027
Open AccessNovel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial
Background: Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti–heart failure therapies include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is). Both classes have demonstrated mortality and morbidity benefits. Although these new therapies have morbidity and mortality benefits, it is not known whether rapid initiation is beneficial when compared with the conventional, slower-stepped approach. Many clinicians have been taught that starting with low-dose therapies and gradually increasing the dose is a safe way of intensifying treatment regimens. Pharmacologically, it is rational to use a combination of drugs that target multiple pathological mechanisms, as there is potential synergism and better therapeutic outcomes. Theoretically, the quicker the right combinations are used, the more likely the beneficial effects will be experienced. However, rapid up-titration must be balanced with patient safety and tolerability. Objective: This study aims to determine if early addition of ARNIs, SGLT2is, β-blockers, and mineralocorticoid receptor antagonists (within 4 weeks), when compared with the same therapies initiated slower (within 6 months), will reduce all-cause mortality and hospitalizations for heart failure in patients with stable heart failure with reduced ejection fraction. Methods: This is a single-center, randomized controlled, double-arm, assessor-blinded, active control, and pragmatic clinical trial. Adults with stable heart failure with reduced ejection fraction and idiopathic dilated cardiomyopathy will be randomized to conventional sequencing (the control arm; over 6 months) of anti–heart failure therapies, and a second arm will receive rapid sequencing (over 4 weeks). Study participants will be followed for 5 years to assess the safety, efficacy, and tolerability of the 2 types of sequencing. Posttrial access and care will be provided to all study participants throughout their lifespan. Results: We are currently in the process of obtaining ethical clearance and funding. Conclusions: We envisage that this study will help support evidence-based medicine and inform clinical practice guidelines on the optimal rate of sequencing of anti–heart failure therapies. A third placebo arm was considered, but costs would be too much and not providing study participants with therapies with known morbidity and mortality benefits may be unethical, in our opinion. Given the post–COVID-19 economic downturn and posttrial access to interventions, a major challenge will be acquiring funding for this study. International Registered Report Identifier (IRRID): PRR1-10.2196/44027
- 22 January 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 483
Stratification of polyisocyanate in two-component waterborne polyurethane films
- 22 January 2024
- Published by Elsevier in Chemical Engineering Journal
- Vol. 483
Stratification of polyisocyanate in two-component waterborne polyurethane films
- 5 October 2023
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 35 (20) , 8417-8425
Studying Hydrogen–Halide Interactions in Lead Halide Perovskite with Isoelectronic Cations
- 5 October 2023
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 35 (20) , 8417-8425
Studying Hydrogen–Halide Interactions in Lead Halide Perovskite with Isoelectronic Cations
- Open Access
- 3 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti–heart failure therapies include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is). Both classes have demonstrated mortality and morbidity benefits. Although these new therapies have morbidity and mortality benefits, it is not known whether rapid initiation is beneficial when compared with the conventional, slower-stepped approach. Many clinicians have been taught that starting with low-dose therapies and gradually increasing the dose is a safe way of intensifying treatment regimens. Pharmacologically, it is rational to use a combination of drugs that target multiple pathological mechanisms, as there is potential synergism and better therapeutic outcomes. Theoretically, the quicker the right combinations are used, the more likely the beneficial effects will be experienced. However, rapid up-titration must be balanced with patient safety and tolerability. OBJECTIVE This study aims to determine if early addition of ARNIs, SGLT2is, β-blockers, and mineralocorticoid receptor antagonists (within 4 weeks), when compared with the same therapies initiated slower (within 6 months), will reduce all-cause mortality and hospitalizations for heart failure in patients with stable heart failure with reduced ejection fraction. METHODS This is a single-center, randomized controlled, double-arm, assessor-blinded, active control, and pragmatic clinical trial. Adults with stable heart failure with reduced ejection fraction and idiopathic dilated cardiomyopathy will be randomized to conventional sequencing (the control arm; over 6 months) of anti–heart failure therapies, and a second arm will receive rapid sequencing (over 4 weeks). Study participants will be followed for 5 years to assess the safety, efficacy, and tolerability of the 2 types of sequencing. Posttrial access and care will be provided to all study participants throughout their lifespan. RESULTS We are currently in the process of obtaining ethical clearance and funding. CONCLUSIONS We envisage that this study will help support evidence-based medicine and inform clinical practice guidelines on the optimal rate of sequencing of anti–heart failure therapies. A third placebo arm was considered, but costs would be too much and not providing study participants with therapies with known morbidity and mortality benefits may be unethical, in our opinion. Given the post–COVID-19 economic downturn and posttrial access to interventions, a major challenge will be acquiring funding for this study. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/44027
- 3 November 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessNovel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Chronic heart failure has high morbidity and mortality, with approximately half of the patients dying within 5 years of diagnosis. Recent additions to the armamentarium of anti–heart failure therapies include angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is). Both classes have demonstrated mortality and morbidity benefits. Although these new therapies have morbidity and mortality benefits, it is not known whether rapid initiation is beneficial when compared with the conventional, slower-stepped approach. Many clinicians have been taught that starting with low-dose therapies and gradually increasing the dose is a safe way of intensifying treatment regimens. Pharmacologically, it is rational to use a combination of drugs that target multiple pathological mechanisms, as there is potential synergism and better therapeutic outcomes. Theoretically, the quicker the right combinations are used, the more likely the beneficial effects will be experienced. However, rapid up-titration must be balanced with patient safety and tolerability. OBJECTIVE This study aims to determine if early addition of ARNIs, SGLT2is, β-blockers, and mineralocorticoid receptor antagonists (within 4 weeks), when compared with the same therapies initiated slower (within 6 months), will reduce all-cause mortality and hospitalizations for heart failure in patients with stable heart failure with reduced ejection fraction. METHODS This is a single-center, randomized controlled, double-arm, assessor-blinded, active control, and pragmatic clinical trial. Adults with stable heart failure with reduced ejection fraction and idiopathic dilated cardiomyopathy will be randomized to conventional sequencing (the control arm; over 6 months) of anti–heart failure therapies, and a second arm will receive rapid sequencing (over 4 weeks). Study participants will be followed for 5 years to assess the safety, efficacy, and tolerability of the 2 types of sequencing. Posttrial access and care will be provided to all study participants throughout their lifespan. RESULTS We are currently in the process of obtaining ethical clearance and funding. CONCLUSIONS We envisage that this study will help support evidence-based medicine and inform clinical practice guidelines on the optimal rate of sequencing of anti–heart failure therapies. A third placebo arm was considered, but costs would be too much and not providing study participants with therapies with known morbidity and mortality benefits may be unethical, in our opinion. Given the post–COVID-19 economic downturn and posttrial access to interventions, a major challenge will be acquiring funding for this study. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/44027
- 24 October 2022
- Published by American Chemical Society (ACS) in ACS Energy Letters
- Vol. 7 (11) , 4081-4088
(3-Aminopropyl)trimethoxysilane Surface Passivation Improves Perovskite Solar Cell Performance by Reducing Surface Recombination Velocity
- 24 October 2022
- Published by American Chemical Society (ACS) in ACS Energy Letters
- Vol. 7 (11) , 4081-4088
(3-Aminopropyl)trimethoxysilane Surface Passivation Improves Perovskite Solar Cell Performance by Reducing Surface Recombination Velocity
- Top Cited Papers
- 23 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6613) , 1425-1430
Deterministic fabrication of 3D/2D perovskite bilayer stacks for durable and efficient solar cells
Realizing solution-processed heterostructures is a long-enduring challenge in halide perovskites because of solvent incompatibilities that disrupt the underlying layer. By leveraging the solvent dielectric constant and Gutmann donor number, we could grow phase-pure two-dimensional (2D) halide perovskite stacks of the desired composition, thickness, and bandgap onto 3D perovskites without dissolving the underlying substrate. Characterization reveals a 3D–2D transition region of 20 nanometers mainly determined by the roughness of the bottom 3D layer. Thickness dependence of the 2D perovskite layer reveals the anticipated trends for n-i-p and p-i-n architectures, which is consistent with band alignment and carrier transport limits for 2D perovskites. We measured a photovoltaic efficiency of 24.5%, with exceptional stability ofT99(time required to preserve 99% of initial photovoltaic efficiency) of >2000 hours, implying that the 3D/2D bilayer inherits the intrinsic durability of 2D perovskite without compromising efficiency.
- 23 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6613) , 1425-1430
Top Cited PapersDeterministic fabrication of 3D/2D perovskite bilayer stacks for durable and efficient solar cells
Realizing solution-processed heterostructures is a long-enduring challenge in halide perovskites because of solvent incompatibilities that disrupt the underlying layer. By leveraging the solvent dielectric constant and Gutmann donor number, we could grow phase-pure two-dimensional (2D) halide perovskite stacks of the desired composition, thickness, and bandgap onto 3D perovskites without dissolving the underlying substrate. Characterization reveals a 3D–2D transition region of 20 nanometers mainly determined by the roughness of the bottom 3D layer. Thickness dependence of the 2D perovskite layer reveals the anticipated trends for n-i-p and p-i-n architectures, which is consistent with band alignment and carrier transport limits for 2D perovskites. We measured a photovoltaic efficiency of 24.5%, with exceptional stability ofT99(time required to preserve 99% of initial photovoltaic efficiency) of >2000 hours, implying that the 3D/2D bilayer inherits the intrinsic durability of 2D perovskite without compromising efficiency.
- 9 February 2022
- Published by American Chemical Society (ACS) in Macromolecules
- Vol. 55 (4) , 1248-1259
Mechanical Size Effect of Freestanding Nanoconfined Polymer Films
- 9 February 2022
- Published by American Chemical Society (ACS) in Macromolecules
- Vol. 55 (4) , 1248-1259
Mechanical Size Effect of Freestanding Nanoconfined Polymer Films
- 25 October 2021
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 37 (43) , 12723-12731
Chemical Composition and Strain at Interfaces between Different Morphologies in Block Copolymer Thin Films
Transitional composition between two thin-film morphologies of the block copolymer, polystyrene-block-poly(tert-butyl acrylate) (PS-b-PtBuA), was investigated using near-field infrared spectroscopy and atomic force microscopy mechanical measurements. These techniques allowed block identification with nanoscale spatial resolution and elucidated the material’s sub-surface composition. PS was found to form coronae around the PtBuA block in spherical valleys on flat areas of the film, and coronae of PtBuA surrounding the PS lamellae were observed at the edge of the polymer film, where parallel lamellae are formed. Furthermore, we found that the peak position and width varied by location, which may be a result of block composition, chain tension, or substrate interaction.
- 25 October 2021
- Published by American Chemical Society (ACS) in Langmuir
- Vol. 37 (43) , 12723-12731
Chemical Composition and Strain at Interfaces between Different Morphologies in Block Copolymer Thin Films
Transitional composition between two thin-film morphologies of the block copolymer, polystyrene-block-poly(tert-butyl acrylate) (PS-b-PtBuA), was investigated using near-field infrared spectroscopy and atomic force microscopy mechanical measurements. These techniques allowed block identification with nanoscale spatial resolution and elucidated the material’s sub-surface composition. PS was found to form coronae around the PtBuA block in spherical valleys on flat areas of the film, and coronae of PtBuA surrounding the PS lamellae were observed at the edge of the polymer film, where parallel lamellae are formed. Furthermore, we found that the peak position and width varied by location, which may be a result of block composition, chain tension, or substrate interaction.
- 12 February 2021
- Published by American Chemical Society (ACS) in ACS Energy Letters
- Vol. 6 (3) , 934-940
Grain Transformation and Degradation Mechanism of Formamidinium and Cesium Lead Iodide Perovskite under Humidity and Light
- 12 February 2021
- Published by American Chemical Society (ACS) in ACS Energy Letters
- Vol. 6 (3) , 934-940
Grain Transformation and Degradation Mechanism of Formamidinium and Cesium Lead Iodide Perovskite under Humidity and Light
- 1 December 2020
- Published by American Chemical Society (ACS) in Macromolecules
- Vol. 53 (24) , 10744-10753
Monitoring Polymer Diffusion in a Waterborne 2K Polyurethane Formulation Based on an Acrylic Polyol Latex
- 1 December 2020
- Published by American Chemical Society (ACS) in Macromolecules
- Vol. 53 (24) , 10744-10753
Monitoring Polymer Diffusion in a Waterborne 2K Polyurethane Formulation Based on an Acrylic Polyol Latex